Bactericidal effects of silver plus titanium dioxide-coated endotracheal tubes on Pseudomonas aeruginosa and Staphylococcus aureus.
OBJECTIVE
Ventilator-associated pneumonia (VAP) is a nosocomial infection resulting in significant morbidity and mortality. Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus) are pathogens associated with VAP. Silver (Ag) coating of endotracheal tubes (ETTs) reduces bacterial colonization, however titanium dioxide (TiO(2)) coating has not been studied.


METHODS
Five types of ETT coatings were applied over silica layer: Ag, solgel TiO(2), solgel TiO(2) with Ag, Degussa P25 TiO(2) (Degussa TiO(2)), and Degussa TiO(2) with Ag. After ETTs were incubated with P. aeruginosa or S. aureus; colonization was determined quantitatively.


RESULTS
Pseudomonas aeruginosa and S. aureus grew for 5 days on standard ETTs. Compared to standard ETTs, P. aeruginosa growth was significantly inhibited by solgel TiO(2) with Ag at 24 hours, and by Degussa TiO(2) with Ag at 24 and 48 hours after inoculation. No significant difference in S. aureus growth was observed between the control and any of the five coatings for 5 days.


CONCLUSIONS
In vitro, solgel TiO(2) with Ag and Degussa TiO(2) with Ag both attenuated P. aeruginosa growth, but demonstrated no effect on S. aureus colonization. Further studies using alternative coating and incorporating UV light exposure are needed to identify their potential utility in reducing VAP.
Tarquinio
Keiko M
KM
Division of Pediatric Critical Care Medicine, Department of Pediatrics, Rhode Island Hospital, The Warren Alpert Medical School, Brown University, Providence, RI, USA. ktarquinio@lifespan.org
Kothurkar
Nikhil K
NK
Goswami
Dharendra Y
DY
Sanders
Ronald C
RC
Zaritsky
Arno L
AL
LeVine
Ann Marie
AM
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry; D002470:Cell Survival / Q000187:drug effects; D020099:Coated Materials, Biocompatible / Q000008:administration & dosage*; D007442:Intubation, Intratracheal / Q000295:instrumentation*; D008422:Materials Testing; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D012834:Silver / Q000008:administration & dosage* / Q000737:chemistry*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014025:Titanium / Q000737:chemistry*
D000900:Anti-Bacterial Agents; D020099:Coated Materials, Biocompatible; C009495:titanium dioxide; D012834:Silver; D014025:Titanium
Pediatrics. 2002 May;109(5):758-64
11986433
J Hosp Infect. 2006 Jan;62(1):58-63
16099072
J Biomed Mater Res B Appl Biomater. 2007 Oct;83(1):169-80
17385236
Technol Health Care. 1999;7(5):359-70
10543420
Interact Cardiovasc Thorac Surg. 2005 Apr;4(2):110-5
17670368
Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903
11934711
JAMA. 1996 Jan 24-31;275(4):308-14
8544272
Crit Care Med. 2003 May;31(5):1312-7
12771596
Science. 1999 May 21;284(5418):1318-22
10334980
Am J Respir Crit Care Med. 1996 Jul;154(1):111-5
8680665
Langmuir. 2008 Dec 2;24(23):13549-55
18980352
Infect Immun. 2005 Mar;73(3):1811-9
15731082
Respir Care. 2005 Jun;50(6):813-36; discussion 836-8
15913471
Artif Organs. 2008 Feb;32(2):167-74
18269355
J Oral Rehabil. 2010 Jan;37(1):63-8
19895430
Respir Care. 2005 Jun;50(6):725-39; discussion 739-41
15913465
Lancet. 1999 Nov 27;354(9193):1851-8
10584721
Eur Respir J. 1999 Mar;13(3):546-51
10232424
Microbiology (Reading). 2007 Aug;153(Pt 8):2435-2446
17660408
Intensive Care Med. 2002 Apr;28(4):426-31
11967596
Infection. 1999;27 Suppl 1:S16-23
10379438
Curr Top Microbiol Immunol. 2008;322:207-28
18453278
Chest. 1996 Jun;109(6):1556-61
8769511
J Hosp Infect. 2004 Jun;57(2):170-4
15183249
Mol Microbiol. 2002 Mar;43(6):1367-78
11952892
J Biomed Mater Res B Appl Biomater. 2008 May;85(2):453-60
18098205
J Oral Rehabil. 2009 Dec;36(12):902-8
19941590
Pediatr Neurosurg. 2008;44(6):444-7
19018152
JAMA. 2008 Aug 20;300(7):805-13
18714060
Photochem Photobiol Sci. 2003 May;2(5):591-6
12803083
Crit Care Med. 2006 Nov;34(11):2766-72
16957639